Apimeds Pharmaceuticals US (APUS) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Apimeds Pharmaceuticals US (APUS).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||
Research And Development | 900K (+150.00%) | 360K (-41.94%) | 620K (-4.62%) | 650K | - | - | - | - | - |
Selling General And Administrative | 11M (+68.86%) | 6.68M (+447.54%) | 1.22M (-39.30%) | 2.01M (+458.33%) | 360K (+28.57%) | 280K (-6.67%) | 300K (-30.23%) | 430K (+59.26%) | 270K |
Operating Expenses | 12M (+73.15%) | 7.04M (+282.61%) | 1.84M (-30.83%) | 2.66M (+638.89%) | 360K (+28.57%) | 280K (-6.67%) | 300K (-30.23%) | 430K (+59.26%) | 270K |
Depreciation And Amortization | 20K (+100.00%) | 10K | - | - | - | - | - | - | - |
Operating Income | |||||||||
Operating Income | -12.19M (+73.15%) | -7.04M (+282.61%) | -1.84M (-30.83%) | -2.66M (+638.89%) | -360.00K (+28.57%) | -280.00K (-6.67%) | -300.00K (-30.23%) | -430.00K (+59.26%) | -270.00K |
Ebit | -12.19M (+73.15%) | -7.04M (+282.61%) | -1.84M (-30.83%) | -2.66M (+638.89%) | -360.00K (+28.57%) | -280.00K (-6.67%) | -300.00K (-30.23%) | -430.00K (+59.26%) | -270.00K |
EBITDA | -12.17M (+53.66%) | -7.92M (+347.46%) | -1.77M (-33.46%) | -2.66M | 450K | -280.00K (-6.67%) | -300.00K (-30.23%) | -430.00K (+59.26%) | -270.00K |
Other Income / Expenses | |||||||||
Interest Income | - | 40K (-33.33%) | 60K (+200.00%) | 20K | - | - | - | - | - |
Interest Expense | 10K | -580.00K | 10K | - | 850K (+2025.00%) | 40K (+33.33%) | 30K (+50.00%) | 20K (-33.33%) | 30K |
Net Interest Income | - | 40K (-33.33%) | 60K (+200.00%) | 20K | - | - | - | - | - |
Other Non Operating Income | -22.87M | 5.91M (+9750.00%) | 60K | - | -40.00K (-63.64%) | -110.00K (+266.67%) | -30.00K (+50.00%) | -20.00K (0.00%) | -20.00K |
Net Income | |||||||||
Net Income From Continuing Operations | -35.06M (+2922.41%) | -1.16M (-34.83%) | -1.78M (-33.08%) | -2.66M (+565.00%) | -400.00K (+29.03%) | -310.00K (-6.06%) | -330.00K (-26.67%) | -450.00K (+50.00%) | -300.00K |
Net Income | -35.06M (+2922.41%) | -1.16M (-34.83%) | -1.78M (-33.08%) | -2.66M (+565.00%) | -400.00K (+29.03%) | -310.00K (-6.06%) | -330.00K (-26.67%) | -450.00K (+50.00%) | -300.00K |